Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P et al..  2018.  Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.. N Engl J Med. 378(6):518-528.

Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al..  2018.  Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med. 378(8):731-739.

Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S et al..  2017.  Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.. J Urol. 198(4):817-823.

Brose MS, Worden FP, Newbold KL, Guo M, Hurria A.  2017.  Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.. J Clin Oncol. 35(23):2692-2699.

Sherman SI, Clary DO, Elisei R, Schlumberger MJ, Cohen EEW, Schöffski P, Wirth LJ, Mangeshkar M, Aftab DT, Brose MS.  2016.  Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.. Cancer. 122(24):3856-3864.

Ross JB, Huh D, Noble LB, Tavazoie SF.  2015.  Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer.. Nat Cell Biol. 17(5):651-64.

McCrea HJ, Bander ED, Venn RA, Reiner AS, J Iorgulescu B, Puchi LA, Schaefer PM, Cederquist G, Greenfield JP.  2015.  Sex, Age, Anatomic Location, and Extent of Resection Influence Outcomes in Children With High-grade Glioma.. Neurosurgery. 77(3):443-52;discussion452-3.

Brunner AM, Sadrzadeh H, Feng Y, Drapkin BJ, Ballen KK, Attar EC, Amrein PC, McAfee SL, Bin Chen Y-, Neuberg DS et al..  2013.  Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.. Am J Hematol. 88(8):642-6.